

**EV0984**

**ePoster Viewing**

**Clinical epidemiology of infections in immunocompromised hosts**

**Epidemiology of febrile events (FE) and safety of early antibiotic discontinuation (AD) in neutropenic patients (pts) with acute lymphoblastic leukaemia (ALL)**

Vladimir Okhmat<sup>\*1</sup>, Galina Klyasova<sup>1</sup>, Vera Troitskaya<sup>1</sup>, Elena Parovichnikova<sup>1</sup>

<sup>1</sup>*National Research Center for Hematology, Moscow, Russian Federation*

**Background:** The aim of this study was to evaluate the epidemiology of FE and safety of early AD in neutropenic pts with ALL on different chemotherapy phases (CP).

**Material/methods:** Single-center, prospective observational study in adults with newly diagnosed ALL treated by «ALL-2009» protocol (NCT01193933) was performed from Jan 2013 till Nov 2015. Pts were followed up for 180 days.

**Results:** Total of 44 pts were enrolled (22-male, 22-female; median age 26 (17-61). On admission hyperleukocytosis was in 25% (11/44) of pts, ECOG score  $\geq 3$  had 61% (27/44).

These pts had 165 CP (1<sup>st</sup> induction–44, 2<sup>nd</sup> induction–42, 1<sup>st</sup> consolidation–40, 2<sup>nd</sup> consolidation–39). Neutropenia was in 38% of CP, median duration 15 (2-45) days, more frequent and prolonged in 1<sup>st</sup> induction then in other CP (68% vs 48% vs 13% vs 21%,  $p=0.05$ ; 23.5 vs 8.5 vs 10 vs 7 days,  $p=0.03$ ).

FE occurred in 23% (38/165) of CP, predominantly in 1<sup>st</sup> induction (57% vs 17% -2<sup>nd</sup> induction vs 15%-1<sup>st</sup> consolidation,  $p=0.0001$ ). None FE were in 2<sup>nd</sup> consolidation.

FE (38) reasons were: fever of unknown origin (FUO) in 21% (8), clinically documented infection (CDI) in 47% (pneumonia-15, cellulitis-3), bloodstream infection (BSI) in 32% (12).

Among BSI pathogens Gram-negative bacteria were in 66% (*E. coli*–3, *Salmonella* spp.–3, *K. pneumoniae*–2, *E. asburiae*–1, *C. youngae*–1), Gram-positive bacteria were in 44% (*B. cereus*–2, *S. aureus*–2, *E. faecium*–1). BSI was polymicrobial in 25% (3/12).

Rate of invasive mycoses (IM) was 16% (7/44): 3-invasive aspergillosis, probable (IA), 1-mixed IA, probable plus mucormycosis, 3-hepatosplenic candidiasis. All IM occurred in induction. Nobody had IM in consolidation ( $p=0.009$ ).

AD was performed in 45% (17/38) of FE in persistently neutropenic pts. At the time of AD median WBC count was  $0.7 \times 10^9/L$  (0.2–0.9). Median time from defervescence till AD was 2.5 (1–3) days in FUO and 7 (1-19) days in CMI and BSI. The median time from AD till neutrophil recovery was 8 (4–29) days.

Fever recurrence (FR) was in 29% (5/17) of pts with AD. FR reasons were: FUO-1, CDI-2 (cellulitis), BSI-1 (*E. cloacae*), IA-1. All pts became afebrile after the start of appropriate antibiotics. Nobody was admitted to ICU and all survived.

Overall 180 days mortality was 7% (3/44), 2 pts died in 1<sup>st</sup> induction (1-IA+mucormycosis, 1-IA+BSI due to *B. cereus*) and 1 after 2<sup>nd</sup> consolidation in follow-up period (BSI due to *Salmonella* spp.).

**Conclusions:** Our study showed relatively low rate of infections (23%) in ALL pts treated by «ALL-2009» protocol. FE prevailed in 1<sup>st</sup> induction, nobody had infections in 2<sup>nd</sup> consolidation. Most pts (79%) had CMI and BSI. Antibiotics were safely stopped in 45% of persistently neutropenic pts. FR was only in 29% of them and did not affect mortality.